⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11932708 | 0.79 | — | — | |
| SCHEMBL19718385 | 0.79 | — | — | |
| SCHEMBL854990 | 0.79 | — | — | |
| SCHEMBL4697461 | 0.79 | CCR4 (0.39) | — | |
| SCHEMBL16742778 | 0.79 | ENPP2 (0.36) | — | |
| SCHEMBL28315930 | 0.76 | HDAC1 (0.31) | — | |
| SCHEMBL5776654 | 0.72 | NPC1 (0.36) | — | |
| SCHEMBL31169393 | 0.72 | CA2 (0.32) | — | |
| Formamide SCHEMBL28176140 | 0.72 | GABRA5 (0.50) | — | |
| SCHEMBL17709818 | 0.72 | CNR1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-10717728-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190352293-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-11-21 | — | — | US | disclosed |
| CN-110382494-A | Substituted pyrazolo [1,5-A ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2019-10-25 | — | — | CN | disclosed |
| US-10351553-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190070178-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2019-03-07 | — | — | US | disclosed |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2018-08-02 | — | — | US | disclosed |
| US-9845319-B2 | Amide substituted thiazoles as modulators of RORyt | Janssen Pharmaceutiuca NV (BE) | 2017-12-19 | — | — | US | disclosed |
| US-20160122335-A1 | AMIDE SUBSTITUTED THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (US) | 2016-05-05 | — | — | US | disclosed |
| CN-101589024-B | Minor groove binders | UNIV STRATHCLYDE | 2014-01-01 | — | — | CN | disclosed |
| US-20110230445-A1 | Substituted Heteroaryls | PFIZER INC | 2011-09-22 | — | — | US | disclosed |
| EP-2344458-A1 | HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS | Pfizer Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7977367-B2 | Substituted imidazole propanamide glucokinase activators | PFIZER INC (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110053934-A1 | COMPOUNDS AND METHODS OF TREATMENT | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2010029461-A1 | HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063063-A1 | Substituted Heteroaryls | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
| CN-100548995-C | The preparation method of 2-thiazole carboxaldehyde compounds | JIUZHOU PHARMA CO LTD (CN) | 2009-10-14 | — | — | CN | disclosed |
| US-20080234267-A1 | Compounds and Methods of Treatment | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| CN-101050204-A | Method for preparing compound of thiazole formaldehyde class | JIUZHOU PHARMA CO LTD ZHEJIANG (CN) | 2007-10-10 | — | — | CN | disclosed |
| EP-0707584-A1 | NOVEL (1-HETEROAZOLYL-1-HETEROCYCLYL)ALKANE DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE AGENTS | Astra Aktiebolag (SE) | 1996-04-24 | — | — | EP | disclosed |